0IV3 Stock Chart & Stats
$1.46
-$0.03(-1.71%)
At close: 4:00 PM EDT
$1.46
-$0.03(-1.71%)
Day’s Range― - ―
52-Week Range$1.04 - $2.00
Previous CloseN/A
Volume48.57K
Average Volume (3M)31.31K
Market Cap
$827.56M
Enterprise Value$807.52
Total Cash (Recent Filing)$300.85M
Total Debt (Recent Filing)$122.14M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 11, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding641,521,000
10 Day Avg. Volume23,030
30 Day Avg. Volume31,312
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.33Price Target Upside196.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$234.00M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Commercial TractionSustained top-line growth and sequential demand expansion indicate durable commercial adoption of RYTELO. Expanding prescribing accounts and management guidance toward the mid‑to‑high end of revenue targets support scalable revenue, improving the firm’s ability to fund operations and reduce reliance on ad hoc financing over the medium term.
Stronger Balance Sheet And Lower LeverageMaterial reduction in leverage and a sizable equity base materially lower refinancing and interest risks. With assets and cash buffers reported, the company has greater flexibility to fund commercial expansion and clinical programs without immediate refinancing, improving financial durability while clinical milestones are pursued.
Scientific Progress And Supporting Real‑world EvidencePositive real‑world evidence and reinforcing analyses strengthen clinical validity of imetelstat, de‑risking late‑stage development and regulatory discussions. Durable scientific support improves the likelihood of adoption, payer acceptance, and competitive differentiation if Phase III outcomes align with these data.
Bears Say
Large Negative Operating And Free Cash FlowPersistent high cash burn meaningfully raises the probability the company will need external funding within the medium term, creating dilution or covenant risk. Even with improving revenue, negative OCF/FCF at this scale constrains strategic optionality and necessitates disciplined spend or financing to sustain operations and trials.
Continued Unprofitability And Negative ReturnsSizable negative margins and a negative ROE indicate the company has yet to convert revenue growth into sustainable profitability. If expanding commercial costs or clinical spending persist, converting to positive returns will require sustained margin improvement or scale, prolonging reliance on external capital and pressuring investor returns.
Rising Gross‑to‑net Deductions Pressure Realized RevenuesHigher and persistent gross‑to‑net deductions reduce per‑unit realized revenue, eroding gross margins and complicating unit economics. For a drug-dependent revenue base, elevated rebates and deductions materially affect cash realization and forecasting, making durable margin expansion harder without price or channel changes.
Geron News
0IV3 FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest share price was $1.04 and its highest was $2.00 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $827.56M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 11, 2026 which is in 95 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 05, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.011.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corp have?
Geron Corp has 641,521,000 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 16.045%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GB:0IV3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (196.80% Upside)
$4.33 (196.80% Upside)
Blogger Sentiment
Bullish
GB:0IV3 Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Company Description
Geron Corp
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
0IV3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.View all GB:0IV3 earnings summaries0IV3 Stock 12 Month Forecast
Average Price Target
$4.33
▲(196.80% Upside)